PRESS RELEASE

Immunocore appoints Bahija Jallal as Chief Executive Officer

Internationally recognised leader strengthens Immunocore’s executive team

(Oxford, UK and Conshohocken, US, 4 January 2019) Immunocore Limited, a leading T Cell Receptor (TCR) biotechnology company, today announces that Bahija Jallal has been appointed as Chief Executive Officer and Director of the Board.

With more than 25 years of international leadership experience within the pharmaceutical industry, Bahija joins Immunocore from AstraZeneca, where she is President of MedImmune, its global biologics research and development arm, and a member of the senior executive team reporting to the CEO.

Since joining MedImmune in 2006, Bahija has overseen the development of several new medicines, including Imfinzi, Fasenra, Lumoxiti, Siliq and FluMist Quadrivalent. Under Bahija’s leadership, MedImmune has significantly boosted its pipeline, expanding from 40 to more than 130 molecules in research and development targeting cancer; respiratory, inflammation, and autoimmunity; cardiovascular, renal and metabolic; and infectious diseases. Bahija has fostered an entrepreneurial culture that resulted in hundreds of patent applications and significant growth in the publication of MedImmune science in high impact journals. She forged industry-first collaborations and led efforts to acquire four independent biotech, big data and technology companies. Bahija also laid the foundation for the creation of an inflammation and autoimmunity carve out as an independent biotech.

Bahija has authored more than 70 peer-reviewed publications and holds more than 15 patents. She serves on the Board of Anthem, Inc. in Indianapolis, Indiana and on the Board of Trustees of the Johns Hopkins University in Baltimore, Maryland. She is a member of the Government-University-Industry Research Roundtable (GUIRR) of the National Science Foundation and is the immediate past President of the board of the Association of Women in Science. In 2017, Bahija was named Woman of the Year by the Healthcare Businesswomen’s Association.

Sir John Bell, Chairman of Immunocore, said: “Bahija is the ideal candidate to lead Immunocore at this transformational point in its development. A champion for science and diversity, Bahija is a highly seasoned pharmaceutical executive with considerable experience in biologics R&D and immuno-oncology. Her appointment will significantly strengthen Immunocore as we advance our lead candidate, IMCgp100, towards commercialisation, and our growing pipeline of TCR candidates through clinical development. I would like to extend my thanks also to Andrew Hotchkiss, who has been a highly capable interim CEO of Immunocore, for his support.”

“I am excited to have the opportunity to head Immunocore, the leader in cutting-edge TCR bispecifics,” said Bahija Jallal, incoming Chief Executive Officer of Immunocore. “With its strong platform, with potential to be applicable in multiple therapy areas, Immunocore has successfully translated its innovative science into the clinic with ongoing pivotal trials in uveal melanoma and clinical and pre-clinical stage programs in other disease areas. I am looking forward to helping the company, and its talented employees, bring innovative T cell receptor-based medicines to patients.”

- Ends -
For more information, please contact:

Immunocore
Zoë Roberts, Communications Manager
T: +44 (0)1235 438600
E: info@immunocore.com
Follow on Twitter: @Immunocore

Consilium Strategic Communications (corporate and financial)
Mary-Jane Elliott/Jessica Hodgson/Chris Welsh
T: +44 (0)203 709 5700
E: Immunocore@consilium-comms.com

About Immunocore
Immunocore, a leading T Cell Receptor (TCR) biotechnology company, is focused on delivering first-in-class biological therapies that have the potential to transform the lives of people with serious diseases. The Company’s primary therapeutic focus is oncology and it also has programs in infectious and autoimmune diseases. Immunocore has a pipeline of proprietary and partnered programs in development and the lead program, IMCgp100, has entered pivotal clinical studies as a treatment for patients with metastatic uveal melanoma. Collaboration partners include Genentech, GlaxoSmithKline, AstraZeneca, Lilly, and the Bill and Melinda Gates Foundation. Immunocore is headquartered at Milton Park, Oxfordshire, UK, with an office outside Philadelphia, USA. The Company is privately held by a broad international investor base. For more information, please visit www.immunocore.com.